PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX

Zenapax 的 I/II 期开放标签药代动力学和安全性研究

• 批准号: 6118435
• 负责人: ROBERT Bruce ETTENGER
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118435
• 关键词: acute disease /disorder; chronic disease /disorder; chronic renal failure; clinical research; clinical trial phase I; dialysis therapy; drug screening /evaluation; homologous transplantation; human subject; human therapy evaluation; immunosuppressive; kidney transplantation; pharmacokinetics; transplant rejection

Kidney transplantation is the treatment of choice for end stage renal disease. Advances in the treatment of allograft rejection have increased the survival of both patients and their grafts. Nevertheless acute and chronic rejection both continue to hamper graft survival. At one year, about 80% of grafts survive about half survive to 8 years. Failed grafts require dialysis and retransplantation when possible. Prolongation of graft survival effectively increases the supply of organs relative to demand.

肾移植是终末期肾病的首选治疗方法。 同种异体移植排斥治疗的进步提高了患者及其移植物的存活率。 然而，急性和慢性排斥反应都继续阻碍移植物的存活。 一年后，约 80% 的移植物存活，约一半存活至 8 年。 如果可能的话，失败的移植物需要透析和重新移植。 移植物存活的延长有效地增加了器官相对于需求的供应。